Cyban Pty Ltd
Andrew Maxwell is a seasoned entrepreneur and advisor with extensive experience in various sectors, including bio-medical, health technology, and venture capital. As the Founder of Chatsworth Associates since 2004, Maxwell has offered strategic guidance to businesses in emerging markets. In addition, Andrew serves as Non-Executive Chairman for Hemideina and Cyban, both focused on innovative health solutions. Maxwell's past roles include Managing Director and CEO of Global Kinetics Corporation, where significant advances in Parkinson's disease monitoring were made, and CEO of ESCOR Private Equity, where a $40 million investment fund was established. Their educational background includes an MBA and MAcc from Bond University. Andrew Maxwell is also actively involved in advisory roles at Bond University's Faculty of Health Sciences & Medicine and previously served on the board of BioMelbourne Network and as Non-Executive Chairman of Agersens.
This person is not in the org chart
This person is not in any teams
Cyban Pty Ltd
Cyban’s next generation brain oxygen monitor delivers unprecedented brain health monitoring in a non-invasive manner. It enables reliable, early detection of brain hypoxia to help reduce mortality and disability, therefore reducing the need for invasive surgical procedures to provide accurate measurement of brain oxygen levels. Our patented technology uses a proprietary sensor design, novel signal processing and multi-functional capability to deliver reliable results from the site of trauma to hospital discharge. Through this technology Cyban is advancing the treatment of brain injuries by accelerating detection, diagnosis accuracy and treatment times.